Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character)

References

• Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427–434.
   PubMed Web of Science ®Google Scholar
• Stange EF, Schroeder BO. Microbiota and mucosal defense in IBD: an update. Expert Rev Gastroenterol Hepatol. 2019;13(10):963–976.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430–1438.
   PubMed Web of Science ®Google Scholar
• Lee JC, Lyons PA, McKinney EF, et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest. 2011;121(10):4170–4179.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006;130(3):650–656.
   PubMed Web of Science ®Google Scholar
• Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010;139(4):1147–1155.
   PubMed Web of Science ®Google Scholar
• Monstad I, Hovde O, Solberg IC, et al. Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies. Ann Gastroenterol. 2014;27(2):95–104.
   PubMedGoogle Scholar
• Weersma RK, Xavier RJ, Weersma RK, et al. Multiomics analyses to deliver the most effective treatment to every patient with inflammatory bowel disease. Gastroenterology. 2018;155(5):e1–e4.
   PubMedGoogle Scholar
• Ventham NT, Kennedy NA, Adams AT, et al. Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease. Nat Commun. 2016;7:13507.
   PubMed Web of Science ®Google Scholar
• Biasci D, Lee JC, Noor NM, et al. A blood-based prognostic biomarker in IBD. Gut. 2019;68(8):1386–1395.
   PubMed Web of Science ®Google Scholar
• Rudolph SJ, Weinberg DI, McCabe R, et al. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci. 2008;53(4):1033–1041.
   PubMed Web of Science ®Google Scholar
• Kennedy NA. PANTS-study (Predicting Nonresponse to Anti-TNF in Crohn’s disease). ECCO; 2018. Available from: https://www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2018/item/op031-clinical-effectiveness-safety-and-immunogenicity-of-anti-tnf-therapy-in-crohn-x2019-s-disease-12-month-data-from-the-pants-study.html
   Google Scholar
• Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–353.
   PubMed Web of Science ®Google Scholar
• Borg-Bartolo SP, Boyapati RK, Satsangi J, et al. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020;9:54.
   Google Scholar
• Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55(2):205–211.
   PubMed Web of Science ®Google Scholar
• Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7415):220–230.
   PubMed Web of Science ®Google Scholar
• Halfvarson J, Brislawn CJ, Lamendella R, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2:17004.
   PubMed Web of Science ®Google Scholar
• Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731–16736.
   PubMed Web of Science ®Google Scholar
• Magnusson MK, Strid H, Sapnara M, et al. Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J Crohns Colitis. 2016;10(8):943–952.
   PubMed Web of Science ®Google Scholar
• Galazzo G, Tedjo DI, Wintjens DSJ, et al. Fecal microbiota dynamics and its relation with disease course in Crohn's disease. J Crohns Colitis. 2019;13(10):1273–1282.
   PubMed Web of Science ®Google Scholar
• Casén C, Vebø HC, Sekelja M, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015;42(1):71–83.
   PubMed Web of Science ®Google Scholar
• Consortium I-C; 2020; Available from: https://cordis.europa.eu/project/rcn/106191_en).htm
   Google Scholar
• Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6.
   PubMedGoogle Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–753.
   PubMed Web of Science ®Google Scholar
• Mokrowiecka A, Kumor A, Jakubczyk E, et al. The application of Montreal classification in different clinical and serological IBD subtypes. Hepatogastroenterology. 2010;57(101):787–793.
   PubMedGoogle Scholar
• Sprakes MB, Ford AC, Warren L, et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis. 2012;6(2):143–153.
   PubMed Web of Science ®Google Scholar
• West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(5):579–589.
   PubMed Web of Science ®Google Scholar
• Osipenko MF, Livzan MA, Skalinskaya MI, et al. Fecal calprotectin concentration in the differential diagnosis of bowel diseases. Ter Arkh. 2015;87(2):30–33.
   PubMed Web of Science ®Google Scholar
• Vebø HC, Sekelja M, Nestestog R, et al. Temporal development of the infant gut microbiota in immunoglobulin E-sensitized and nonsensitized children determined by the GA-map infant array. Clin Vac Immunol. 2011;18(8):1326–1335.
   PubMedGoogle Scholar
• R: a language and environment for statistical computing; 2019. Available from: https://www.R-project.org/
   Google Scholar
• Varela E, Manichanh C, Gallart M, et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther. 2013;38(2):151–161.
   PubMed Web of Science ®Google Scholar
• Knox NC, Forbes JD, Peterson CL, et al. The gut microbiome in inflammatory bowel disease: lessons learned from other immune-mediated inflammatory diseases. Am J Gastroenterol. 2019;114(7):1051–1070.
   PubMed Web of Science ®Google Scholar
• Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology. 2017;152(2):327–339.e4.
   PubMed Web of Science ®Google Scholar
• Sokol H, Seksik P, Rigottier-Gois L, et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(2):106–111.
   PubMed Web of Science ®Google Scholar
• Engels C, Ruscheweyh H-J, Beerenwinkel N, et al. The common gut microbe Eubacterium hallii also contributes to intestinal propionate formation. Front Microbiol. 2016;7:713.
   PubMed Web of Science ®Google Scholar
• Satokari R. Contentious host-microbiota relationship in inflammatory bowel disease—can foes become friends again? Scand J Gastroenterol. 2015;50(1):34–42.
   PubMed Web of Science ®Google Scholar
• Miquel S, Martin R, Rossi O, et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2013;16(3):255–261.
   PubMed Web of Science ®Google Scholar
• Dethlefsen L, Eckburg PB, Bik EM, et al. Assembly of the human intestinal microbiota. Trends Ecol Evol (Amst). 2006;21(9):517–523.
   PubMed Web of Science ®Google Scholar
• Hold GL, Smith M, Grange C, et al. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol. 2014;20(5):1192–1210.
   PubMed Web of Science ®Google Scholar
• Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13(9):R79.
   PubMed Web of Science ®Google Scholar
• Papa E, Docktor M, Smillie C, et al. Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One. 2012;7(6):e39242.
   PubMed Web of Science ®Google Scholar
• Pascal V, Pozuelo M, Borruel N, et al. A microbial signature for Crohn's disease. Gut. 2017;66(5):813–822.
   PubMed Web of Science ®Google Scholar
• Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut. 2011;60(5):631–637.
   PubMed Web of Science ®Google Scholar
• Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275–1283.
   PubMed Web of Science ®Google Scholar
• Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58(2):176–180.
   PubMed Web of Science ®Google Scholar
• Bjarnason I. The use of fecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol (NY). 2017;13(1):53–56.
   PubMedGoogle Scholar
• Zhulina Y, Cao Y, Amcoff K, et al. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease. Aliment Pharmacol Ther. 2016;44(5):495–504.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Sasaki T, Itoh K, et al. A soluble fiber diet increases Bacteroides fragilis group and IgA production in the gut. Appl Environ Microbiol. 2020;86(13):e00405–e00420.
   PubMed Web of Science ®Google Scholar
• Hiippala K, Kainulainen V, Suutarinen M, et al. Isolation of anti-inflammatory and epithelium reinforcing bacteroides and Parabacteroides spp. from a healthy fecal donor. Nutrients. 2020;12(4):935.
   Web of Science ®Google Scholar
• Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014;15(3):382–392.
   PubMed Web of Science ®Google Scholar
• Gorkiewicz G, Thallinger GG, Trajanoski S, et al. Alterations in the colonic microbiota in response to osmotic diarrhea. PLoS One. 2013;8(2):e55817.
   PubMed Web of Science ®Google Scholar
• Björkqvist O, Repsilber D, Seifert M, et al. Alterations in the relative abundance of Faecalibacterium prausnitzii correlate with changes in fecal calprotectin in patients with ileal Crohn's disease: a longitudinal study. Scand J Gastroenterol. 2019;54(5):577–585.
   PubMed Web of Science ®Google Scholar
• Olbjørn C, Cvancarova Småstuen M, Thiis-Evensen E, et al. Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease – associations with disease phenotype, treatment, and outcome. Clin Exp Gastroenterol. 2019;12:37–49.
   PubMed Web of Science ®Google Scholar
• Willing B, Halfvarson J, Dicksved J, et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis. 2009;15(5):653–660.
   PubMed Web of Science ®Google Scholar
• Schirmer M, Franzosa EA, Lloyd-Price J, et al. Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. Nat Microbiol. 2018;3(3):337–346.
   PubMed Web of Science ®Google Scholar
• Clerc F, Novokmet M, Dotz V, et al. Plasma N-glycan signatures are associated with features of inflammatory bowel diseases. Gastroenterology. 2018;155(3):829–843.
   PubMed Web of Science ®Google Scholar
• Kalla R, Adams A, Vatn S, et al. Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character Study. Gastroenterology. 2017;152(5):S606–S607.
   Web of Science ®Google Scholar
• Ananthakrishnan AN, Luo C, Yajnik V, et al. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host Microbe. 2017;21(5):603–610.e3.
   PubMed Web of Science ®Google Scholar
• Doherty MK, Ding T, Koumpouras C, et al. Fecal microbiota signatures are associated with response to ustekinumab therapy among Crohn's disease patients. mBio. 2018;9(2):e02120.
   PubMed Web of Science ®Google Scholar
• Moen AEF, Lindstrøm JC, Tannaes TM, et al. The prevalence and transcriptional activity of the mucosal microbiota of ulcerative colitis patients. Sci Rep. 2018;8(1):17278.
   PubMed Web of Science ®Google Scholar
• Moen AEF, Tannaes TM, Vatn S, et al. Simultaneous purification of DNA and RNA from microbiota in a single colonic mucosal biopsy. BMC Res Notes. 2016;9:328.
   PubMedGoogle Scholar
• Chiara MM, Franco S, Marco P, et al. Nutrition, IBD and gut microbiota: a review. Nutrients. 2020;12(4):944.
   Web of Science ®Google Scholar
• Senghor B, Sokhna C, Ruimy R, et al. Gut microbiota diversity according to dietary habits and geographical provenance. Hum Microb J. 2018;7–8:1–9.
   Google Scholar